Claims + Tests
Claims + Tests
At Salvida, we believe skincare claims should be earned - not invented.
Walk through any pharmacy, beauty retailer or cosmetics aisle and you’ll see countless products using vague marketing terms or making exaggerated claims that aren’t backed by proper testing.
That’s why we created this page.
Here, you’ll find a clear breakdown of the clinical and instrumental testing we conduct, who performs it and what the results actually mean. We explain our testing methods in plain English and show exactly how our product claims are supported.
Because when it comes to sensitive skin, transparency matters.
General
We use two types of testing: clinical testing and consumer studies. Both play an important role in ensuring our products perform as promised.
Our clinical testing includes clinical trials along with in-vivo efficacy and safety assessments. These independent, third-party tests help substantiate claims such as:
+ Dermatologist Tested
+ Safe for Sensitive Skin
+ Proven to Restore the Skin Barrier
Consumer studies help us understand real-world experiences, including first impressions, product feel and overall satisfaction.
In our 2026 consumer study, 172 people living with sensitive, reactive and compromised skin trialled the full range at home over four weeks. They told us:
+ 9 in 10 would recommend Salvida to family and friends
+ 93% said their skin looked healthier and more radiant
+ 88% said their skin looked or felt noticeably better after four weeks
+ 80% agreed the formulation improved their skin barrier within 24 hours
Yes, for Barrier NPR+, Bodyguard and Every Day, Everywhere. All of their clinical testing and consumer studies are conducted by independent, third-party accredited research facilities to help ensure objective and reliable results.
Barrier Reset Spray is the exception. It is made for us by an Australian specialist in stabilised hypochlorous acid and its testing was carried out in-house by that manufacturer. We state this clearly beside each Barrier Reset Spray claim below.
We maintain strict quality standards through regular testing for stability, safety and performance. Every batch undergoes rigorous quality checks to help ensure consistency, reliability and product integrity.
Barrier NPR+ Claims
Barrier NPR+ was evaluated in an independent consumer perception study involving 172 participants experiencing concerns such as:
+ eczema
+ dermatitis
+ psoriasis
+ topical steroid withdrawal symptoms
+ sensitive or reactive skin
+ rosacea
+ acne
9 out of 10 participants said they would recommend it for sensitive, reactive and compromised skin barriers.
Survey conducted by Home Tester Club from 12 December 2025 to 20 January 2026, 172 members surveyed. Full results, reviews and testimonials can be found HERE.
TL;DR
This clinical study tested whether Barrier NPR+ helped moisturise the skin and support the skin barrier after one application.
18 adults with dry skin had the product applied to one area of their forearm while another area was left untreated for comparison.
Researchers then used scientific skin-testing devices over an 8-hour period to measure:
+ How hydrated the skin became
+ Whether the product helped prevent water from escaping through the skin
The results showed that Barrier NPR+ maintains the skin barrier.
Study Title:
Assessment in Human of the Effect on Hydration Level and on Transepidermal Water Loss of Several Cosmetic Products After Single Application to the Skin - Instrumental Measurements
Study Reference Number:
24-0746/0
Conducted:
Study start: 9 September 2024 - Study end: 10 September 2024
Final report issued: 26 September 2024
EUROFINS PRODUCT TESTING, COSMETICS & PERSONAL CARE SPAIN, S.L.U. (2024). Assessment in Human of the Effect on Hydration Level and on Transepidermal Water Loss of Several Cosmetic Products After Single Application to the Skin - Instrumental Measurements. Study Report Ref. 24-0746/0. Barcelona, Spain.
This was an open-label, intra-individual clinical instrumental study conducted on 18 healthy adult participants with dry forearm skin aged between 20 and 66 years.
The purpose of the study was to evaluate whether the product could:
+ Increase skin hydration
+ Help maintain the skin barrier by reducing or preventing excessive water loss from the skin
Each participant acted as their own control. Researchers applied the product to a designated area on the forearm while another untreated area served as the comparison control.
Two validated scientific instruments were used:
+ Corneometer CM 825® - measures hydration levels in the outer layer of the skin
+ Tewameter TM 300® - measures transepidermal water loss (TEWL), an indicator of skin barrier integrity
Measurements were taken:
+ Before application
+ 1 hour after application
+ 3 hours after application
+ 6 hours after application
+ 8 hours after application
Statistical analysis was performed to determine whether changes were significant compared with untreated skin.
TL;DR
This clinical study tested whether Barrier NPR+ helped moisturise the skin and support the skin barrier after one application.
18 adults with dry skin had the product applied to one area of their forearm while another area was left untreated for comparison.
Researchers then used scientific skin-testing devices over an 8-hour period to measure:
+ How hydrated the skin became
+ Whether the product helped prevent water from escaping through the skin
The results showed that Barrier NPR+ maintains the skin barrier.
Study Title:
Assessment in Human of the Effect on Hydration Level and on Transepidermal Water Loss of Several Cosmetic Products After Single Application to the Skin - Instrumental Measurements
Study Reference Number:
24-0746/0
Conducted:
Study start: 9 September 2024 - Study end: 10 September 2024
Final report issued: 26 September 2024
EUROFINS PRODUCT TESTING, COSMETICS & PERSONAL CARE SPAIN, S.L.U. (2024). Assessment in Human of the Effect on Hydration Level and on Transepidermal Water Loss of Several Cosmetic Products After Single Application to the Skin - Instrumental Measurements. Study Report Ref. 24-0746/0. Barcelona, Spain.
This was an open-label, intra-individual clinical instrumental study conducted on 18 healthy adult participants with dry forearm skin aged between 20 and 66 years.
The purpose of the study was to evaluate whether the product could:
+ Increase skin hydration
+ Help maintain the skin barrier by reducing or preventing excessive water loss from the skin
Each participant acted as their own control. Researchers applied the product to a designated area on the forearm while another untreated area served as the comparison control.
Two validated scientific instruments were used:
+ Corneometer CM 825® - measures hydration levels in the outer layer of the skin
+ Tewameter TM 300® - measures transepidermal water loss (TEWL), an indicator of skin barrier integrity
Measurements were taken:
+ Before application
+ 1 hour after application
+ 3 hours after application
+ 6 hours after application
+ 8 hours after application
Statistical analysis was performed to determine whether changes were significant compared with untreated skin.
TL;DR
This clinical study tested whether Barrier NPR+ helped moisturise the skin and support the skin barrier after one application.
18 adults with dry skin had the product applied to one area of their forearm while another area was left untreated for comparison.
Researchers then used scientific skin-testing devices over an 8-hour period to measure:
+ How hydrated the skin became
+ Whether the product helped prevent water from escaping through the skin
The results showed that Barrier NPR+ maintains the skin barrier.
Study Title:
Assessment in Human of the Effect on Hydration Level and on Transepidermal Water Loss of Several Cosmetic Products After Single Application to the Skin - Instrumental Measurements
Study Reference Number:
24-0746/0
Conducted:
Study start: 9 September 2024 - Study end: 10 September 2024
Final report issued: 26 September 2024
EUROFINS PRODUCT TESTING, COSMETICS & PERSONAL CARE SPAIN, S.L.U. (2024). Assessment in Human of the Effect on Hydration Level and on Transepidermal Water Loss of Several Cosmetic Products After Single Application to the Skin - Instrumental Measurements. Study Report Ref. 24-0746/0. Barcelona, Spain.
This was an open-label, intra-individual clinical instrumental study conducted on 18 healthy adult participants with dry forearm skin aged between 20 and 66 years.
The purpose of the study was to evaluate whether the product could:
+ Increase skin hydration
+ Help maintain the skin barrier by reducing or preventing excessive water loss from the skin
Each participant acted as their own control. Researchers applied the product to a designated area on the forearm while another untreated area served as the comparison control.
Two validated scientific instruments were used:
+ Corneometer CM 825® - measures hydration levels in the outer layer of the skin
+ Tewameter TM 300® - measures transepidermal water loss (TEWL), an indicator of skin barrier integrity
Measurements were taken:
+ Before application
+ 1 hour after application
+ 3 hours after application
+ 6 hours after application
+ 8 hours after application
Statistical analysis was performed to determine whether changes were significant compared with untreated skin.
TL;DR
This clinical study tested whether Barrier NPR+ caused irritation or skin reactions after application under occlusive patch test conditions.
30 healthy adult participants had the product applied to the outer arm under a sealed patch for 48 hours. Researchers then assessed the skin for signs of irritation including redness (erythema), swelling (oedema), papules, vesicles or other visible reactions.
The results showed no irritation or adverse skin reactions in any participant at either the 48-hour or 72-hour assessment points.
The product achieved an Average Irritation Index (Xir) of 0.00, indicating excellent skin compatibility and classification as “Not Irritating”.
Study Title:
Assessment of Dermal Compatibility (Irritant Potential) - Occlusive Patch Test
Study Reference Number:
2024-0226-2
Conducted:
Sample received: 29 July 2024
Study start: 1 August 2024
Study end: 7 August 2024
Final report issued:
8 August 2024
Cosmetic Testing Lab. (2024). Assessment of Dermal Compatibility (Irritant Potential) - Occlusive Patch Test. Final Report No. 2024-0226-2.
This was an occlusive patch test conducted on 30 healthy adult participants aged between 18 and 65 years to assess the skin compatibility and irritant potential of Barrier NPR+ under normal conditions of use.
The purpose of the study was to determine whether the product caused irritation or adverse skin reactions when applied directly to human skin.
Researchers assessed:
+ Skin irritation potential
+ Signs of redness (erythema)
+ Swelling (oedema)
+ Other visible irritation responses including papules, vesicles or blistering
Approximately 0.2g or 0.2ml of product was applied to intact skin on the outer arm under an occlusive patch for 48 hours.
Skin assessments were then performed:
+ 15 minutes after patch removal
+ 24 hours after patch removal (corresponding to 48-hour and 72-hour evaluation timepoints)
Researchers used a standardised irritation grading scale to assess:
+ Erythema (redness)
+ Oedema (swelling)
Each reaction was assigned a numerical score, which was then used to calculate the Average Irritation Index (Xir).
Results showed:
+ No erythema in any participant
+ No oedema in any participant
+ No visible irritation reactions at either assessment point
The calculated Average Irritation Index (Xir) was:
+ Xir = 0.00
According to the study classification scale:
+ Xir < 0.5 = Not irritating
The study concluded that Barrier NPR+ was classified as:
+ NOT IRRITATING
Main takeaway:
Barrier NPR+ demonstrated excellent skin compatibility in a 30-person occlusive patch test, with no observed irritation or adverse skin reactions and an Average Irritation Index (Xir) of 0.00.
TL;DR
This Human Repeat Insult Patch Test (HRIPT) evaluated whether Barrier NPR+ had the potential to cause skin irritation or trigger allergic sensitisation after repeated exposure.
56 adult participants underwent repeated patch applications over a six-week study period under controlled clinical conditions.
The results showed that Barrier NPR+ did not demonstrate the potential to cause dermal irritation or induce sensitisation in any participant.
Study Title:
Repeat Insult Patch Test (HRIPT)
Study Reference Number:
ECRLNJ2024-0679
Conducted:
Study start: 7 August 2024
Study end: 20 September 2024
Final report issued: 26 September 2024
Eurofins CRL. (2024). Repeat Insult Patch Test. Study Report ECRLNJ2024-0679.
This was a Human Repeat Insult Patch Test (HRIPT) conducted on 56 adult participants to evaluate the dermal compatibility and sensitisation potential of Barrier NPR+ after repeated exposure under controlled conditions.
The purpose of the study was to determine whether the product could:
+ Cause skin irritation after repeated application
+ Induce sensitisation or allergic skin reactions over time
HRIPT studies are considered one of the industry standards for assessing whether a topical skincare product has the potential to trigger irritation or allergic contact sensitisation in humans following repeated exposure.
Participants underwent repeated patch applications over approximately six weeks, with skin responses monitored throughout the study period.
Researchers assessed:
+ Signs of dermal irritation
+ Sensitisation reactions
+ Adverse skin responses following repeated exposure
The results showed:
+ No evidence of dermal irritation
+ No evidence of induced sensitisation in any participant
The study concluded that Barrier NPR+:
+ “Did not demonstrate a potential for eliciting dermal irritation or inducing sensitization.”
Main takeaway:
In a 56-person Human Repeat Insult Patch Test (HRIPT), Barrier NPR+ demonstrated excellent skin compatibility with no observed irritation or sensitisation responses following repeated exposure.
Barrier NPR+ has undergone clinical skin compatibility testing under dermatological assessment conditions to evaluate irritation and sensitisation potential.
Supporting studies
Occlusive Patch Test - Dermal Compatibility Study
Cosmetic Testing Lab (2024)
30 participants
Result: Average Irritation Index (Xir) = 0.00 with no observed irritation reactions.
Human Repeat Insult Patch Test (HRIPT)
Eurofins CRL Study #ECRLNJ2024-0679
56 participants
Result: “Did not demonstrate a potential for eliciting dermal irritation or inducing sensitization."
The Eczema Association of Australasia reviewed the Barrier Reset Spray formulation and confirmed it passed their ingredient assessment. This is an assessment of the ingredients, not a clinical or efficacy test.
Supporting documentation:
Ingredient Assessment
Eczema Association of Australasia, 18 August 2026
Result: Passed.
These claims are established during formulation and confirmed again during manufacturing through detailed ingredient verification and review of all product INCI declarations.
Barrier NPR+ is formulated without animal-derived ingredients, added fragrance or corticosteroids. All raw materials and ingredient specifications are reviewed to ensure compliance with these standards.
Bodyguard Claims
Bodyguard was evaluated in an independent consumer perception study involving 172 participants experiencing concerns such as:
+ eczema
+ dermatitis
+ psoriasis
+ topical steroid withdrawal symptoms
+ sensitive or reactive skin
+ rosacea
+ acne
9 out of 10 participants said they would recommend it for sensitive, reactive and compromised skin barriers.
Survey conducted by Home Tester Club from 12 December 2025 to 20 January 2026, 172 members surveyed. Full results, reviews and testimonials can be found HERE.
TL;DR
This clinical study tested whether Bodyguard helped moisturise the skin and support the skin barrier after one application.
18 adults with dry skin had the product applied to one area of their forearm while another area was left untreated for comparison.
Researchers then used scientific skin-testing devices over an 8-hour period to measure:
+ How hydrated the skin became
+ Whether the product helped prevent water from escaping through the skin
The results showed that Bodyguard maintains the skin barrier.
Study Title:
Assessment in Human of the Effect on Hydration Level and on Transepidermal Water Loss of Several Cosmetic Products After Single Application to the Skin - Instrumental Measurements
Study Reference Number:
24-0746/0
Conducted:
Study start: 9 September 2024 - Study end: 10 September 2024
Final report issued: 26 September 2024
EUROFINS PRODUCT TESTING, COSMETICS & PERSONAL CARE SPAIN, S.L.U. (2024).
Assessment in Human of the Effect on Hydration Level and on Transepidermal Water Loss of Several Cosmetic Products After Single Application to the Skin - Instrumental Measurements. Study Report Ref. 24-0746/0. Barcelona, Spain.
This was an open-label, intra-individual clinical instrumental study conducted on 18 healthy adult participants with dry forearm skin aged between 20 and 66 years.
The purpose of the study was to evaluate whether the product could:
+ Increase skin hydration
+ Help maintain the skin barrier by reducing or preventing excessive water loss from the skin
Each participant acted as their own control. Researchers applied the product to a designated area on the forearm while another untreated area served as the comparison control.
Two validated scientific instruments were used:
+ Corneometer CM 825® - measures hydration levels in the outer layer of the skin
+ Tewameter TM 300® - measures transepidermal water loss (TEWL), an indicator of skin barrier integrity
Measurements were taken:
+ Before application
+ 1 hour after application
+ 3 hours after application
+ 6 hours after application
+ 8 hours after application
Statistical analysis was performed to determine whether changes were significant compared with untreated skin.
TL;DR
This clinical study tested whether Bodyguard helped moisturise the skin and support the skin barrier after one application.
18 adults with dry skin had the product applied to one area of their forearm while another area was left untreated for comparison.
Researchers then used scientific skin-testing devices over an 8-hour period to measure:
+ How hydrated the skin became
+ Whether the product helped prevent water from escaping through the skin
The results showed that Bodyguard maintains the skin barrier.
Study Title:
Assessment in Human of the Effect on Hydration Level and on Transepidermal Water Loss of Several Cosmetic Products After Single Application to the Skin - Instrumental Measurements
Study Reference Number:
24-0746/0
Conducted:
Study start: 9 September 2024 - Study end: 10 September 2024
Final report issued: 26 September 2024
EUROFINS PRODUCT TESTING, COSMETICS & PERSONAL CARE SPAIN, S.L.U. (2024).
Assessment in Human of the Effect on Hydration Level and on Transepidermal Water Loss of Several Cosmetic Products After Single Application to the Skin - Instrumental Measurements. Study Report Ref. 24-0746/0. Barcelona, Spain.
This was an open-label, intra-individual clinical instrumental study conducted on 18 healthy adult participants with dry forearm skin aged between 20 and 66 years.
The purpose of the study was to evaluate whether the product could:
+ Increase skin hydration
+ Help maintain the skin barrier by reducing or preventing excessive water loss from the skin
Each participant acted as their own control. Researchers applied the product to a designated area on the forearm while another untreated area served as the comparison control.
Two validated scientific instruments were used:
+ Corneometer CM 825® - measures hydration levels in the outer layer of the skin
+ Tewameter TM 300® - measures transepidermal water loss (TEWL), an indicator of skin barrier integrity
Measurements were taken:
+ Before application
+ 1 hour after application
+ 3 hours after application
+ 6 hours after application
+ 8 hours after application
Statistical analysis was performed to determine whether changes were significant compared with untreated skin.
TL;DR
This clinical study tested whether Bodyguard caused irritation or skin reactions after repeated application under maximised patch-test conditions over a 14-day period.
31 adults with self-declared sensitive skin had the product repeatedly applied to the same area of the upper back under semi-occlusive patches to assess cumulative irritation potential and overall skin compatibility.
Researchers monitored participants throughout the study for visible skin reactions including redness, swelling, dryness, itching, papules, vesicles and other irritation responses.
The results showed that Bodyguard induced no irritation reactions throughout the study and demonstrated very good skin compatibility.
The Mean Daily Irritation Score (MDIS) remained 0 throughout testing, indicating no observed irritation or adverse skin reactions under study conditions.
Study Title:
Evaluation of the Cumulative Irritation Potential of One Product After Repeated Application Under Patch in Human - 14-Day Cumulative Irritability Test
Study Reference Number:
EUROFINS EVIC Romania ER 24/194
Conducted:
Study start: 21 October 2024
Study completion: 4 November 2024
Final report issued: 22 November 2024
EUROFINS EVIC Product Testing Romania S.R.L. (2024). Evaluation of the Cumulative Irritation Potential of One Product After Repeated Application Under Patch in Human - 14-Day Cumulative Irritability Test. Study Report ER 24/194. Bucharest, Romania.
This was a monocentric, simple-blind cumulative irritation patch test conducted on 31 valid adult participants aged between 20 and 70 years with self-declared sensitive skin.
The purpose of the study was to evaluate whether repeated applications of Bodyguard could:
+ Cause cumulative skin irritation
+ Trigger visible skin reactions after repeated exposure
+ Demonstrate good skin compatibility under maximised exposure conditions
Participants received six repeated applications of the product over a two-week period to the same area of the upper back under semi-occlusive patch conditions.
Each participant also had a control site treated with distilled water for comparison.
Skin assessments were performed throughout the study by dermatologists and trained clinical investigators.
Researchers monitored for:
+ Redness (erythema)
+ Swelling or oedema
+ Dryness
+ Itching
+ Papules
+ Vesicles
+ Fissuring
+ Other visible irritation reactions
The study used standardised irritation scoring methods including:
+ Daily Irritation Score (DIS)
+ Mean Daily Irritation Score (MDIS)
+ Mean Irritation Index (MII)
According to the study classification scale:
+ MII < 0.20 = Not irritating
The results showed:
+ No irritation reactions observed during repeated application
+ Very good skin compatibility under study conditions
The study concluded that:
+ “The product induced no reaction of irritation and has a very good skin compatibility.”
Main takeaway:
Bodyguard demonstrated excellent skin compatibility in a 14-day repeated application cumulative irritation study, with no observed irritation reactions under maximised exposure conditions.
MDIS = 0 indicated no measurable irritation response throughout the study period.
Bodyguard has undergone clinical skin compatibility testing under dermatological assessment conditions to evaluate irritation potential and overall skin compatibility.
Supporting studies:
Occlusive Patch Test - Dermal
Compatibility Study
Cosmetic Testing Lab (2024)
30 participants
Result: Average Irritation Index (Xir) = 0.00 with no observed irritation reactions.
14-Day Cumulative Irritability Test
EUROFINS EVIC Romania Study ER 24/194
31 valid participants with sensitive skin
Result: “The product induced no reaction of irritation and has a very good skin compatibility.”
Gentle pH
Bodyguard maintained a stable mildly acidic pH throughout 12-week stability testing under multiple storage conditions.
Supporting study:
12-Week Stability and Compatibility Test
Cosmetic Testing Lab (2024)
Result: Product pH remained stable between pH 6.12-6.38 throughout testing.
TL;DR
This clinical study confirmed that 100% of participants achieved very good skin compatibility with Bodyguard after repeated application under maximised patch-test conditions over a 14-day period.
31 adults with self-declared sensitive skin had the product repeatedly applied to the same area of the upper back under semi-occlusive patches to assess cumulative irritation potential and overall skin compatibility.
Researchers monitored participants throughout the study for visible skin reactions including redness, swelling, dryness, itching, papules, vesicles and other irritation responses.
Every one of the 31 participants completed the study with no irritation reactions recorded, giving Bodyguard a 100% very good skin compatibility result.
Study Title:
Evaluation of the Cumulative Irritation Potential of One Product After Repeated Application Under Patch in Human - 14-Day Cumulative Irritability Test
Study Reference Number:
EUROFINS EVIC Romania ER 24/194
Conducted:
Study start: 21 October 2024
Study completion: 4 November 2024
Final report issued: 22 November 2024
EUROFINS EVIC Product Testing Romania S.R.L. (2024). Evaluation of the Cumulative Irritation Potential of One Product After Repeated Application Under Patch in Human - 14-Day Cumulative Irritability Test. Study Report ER 24/194. Bucharest, Romania.
This was a monocentric, simple-blind cumulative irritation patch test conducted on 31 valid adult participants aged between 20 and 70 years with self-declared sensitive skin.
The purpose of the study was to evaluate whether repeated applications of Bodyguard could:
+ Cause cumulative skin irritation
+ Trigger visible skin reactions after repeated exposure
+ Demonstrate good skin compatibility under maximised exposure conditions
Participants received six repeated applications of the product over a two-week period to the same area of the upper back under semi-occlusive patch conditions.
Each participant also had a control site treated with distilled water for comparison.
Skin assessments were performed throughout the study by dermatologists and trained clinical investigators.
Researchers monitored for:
+ Redness (erythema)
+ Swelling or oedema
+ Dryness
+ Itching
+ Papules
+ Vesicles
+ Fissuring
+ Other visible irritation reactions
The study used standardised irritation scoring methods including:
+ Daily Irritation Score (DIS)
+ Mean Daily Irritation Score (MDIS)
+ Mean Irritation Index (MII)
According to the study classification scale:
+ MII < 0.20 = Not irritating
The results showed:
+ 100% of participants achieved very good skin compatibility
+ No irritation reactions observed during repeated application
The study concluded that:
+ “The product induced no reaction of irritation and has a very good skin compatibility.”
Main takeaway:
Bodyguard achieved 100% very good skin compatibility in a 14-day repeated application cumulative irritation study, with every participant completing testing free of irritation reactions under maximised exposure conditions.
Bodyguard contains a pre and postbiotic complex. In a study, 10 volunteers aged 22 to 54 applied a cream containing 3% of the complex to one forearm and a placebo cream to the other, twice daily for 15 days.
The proportion of Firmicutes on the skin fell by 38% and Actinobacteria by 19%, and bacterial diversity increased. Firmicutes is the bacterial group that includes the genus Staphylococcus. The study measured the group as a whole, not Staphylococcus on its own.
The Eczema Association of Australasia reviewed the Barrier Reset Spray formulation and confirmed it passed their ingredient assessment. This is an assessment of the ingredients, not a clinical or efficacy test.
Supporting documentation:
Ingredient Assessment
Eczema Association of Australasia, 18 August 2026
Result: Passed.
These claims are established during formulation and confirmed again during manufacturing through detailed ingredient verification and review of all product INCI declarations.
Bodyguard is formulated without animal-derived ingredients, added fragrance or corticosteroids. All raw materials and ingredient specifications are reviewed to ensure compliance with these standards.
Every Day, Everywhere Claims
Every Day, Everywhere was evaluated in an independent consumer perception study involving 172 participants experiencing concerns such as:
+ eczema
+ dermatitis
+ psoriasis
+ topical steroid withdrawal symptoms
+ sensitive or reactive skin
+ rosacea
+ acne
9 out of 10 participants said they would recommend it for sensitive, reactive and compromised skin barriers.
Survey conducted by Home Tester Club from 12 December 2025 to 20 January 2026, 172 members surveyed. Full results, reviews and testimonials can be found HERE.
TL;DR
This clinical study tested whether Every Day, Everywhere caused irritation or skin reactions after repeated application under maximised patch-test conditions over a 14-day period.
31 adults with self-declared sensitive skin had the product repeatedly applied to the same area of the upper back under semi-occlusive patches to assess cumulative irritation potential and overall skin compatibility.
Researchers monitored participants throughout the study for visible skin reactions including redness, swelling, dryness, itching, papules, vesicles and other irritation responses.
The results showed that Every Day, Everywhere induced no irritation reactions throughout the study and demonstrated very good skin compatibility.
The Mean Daily Irritation Score (MDIS) remained 0 throughout testing, indicating no observed irritation or adverse skin reactions under study conditions.
Study Title:
Evaluation of the Cumulative Irritation Potential of One Product After Repeated Application Under Patch in Human - 14-Day Cumulative Irritability Test
Study Reference Number:
EUROFINS EVIC Romania ER 24/194 / 24-0612
Conducted:
Study start: 21 October 2024
Study completion: 4 November 2024
Final report issued: 22 November 2024
EUROFINS EVIC Product Testing Romania S.R.L. (2024). Evaluation of the Cumulative Irritation Potential of One Product After Repeated Application Under Patch in Human - 14-Day Cumulative Irritability Test. Study Report ER 24/194 / 24-0612. Bucharest, Romania.
This was a monocentric, simple-blind cumulative irritation patch test conducted on 31 valid adult participants aged between 20 and 70 years with self-declared sensitive skin.
The purpose of the study was to evaluate whether repeated applications of Every Day, Everywhere could:
+ Cause cumulative skin irritation
+ Trigger visible skin reactions after repeated exposure
+ Demonstrate good skin compatibility under maximised exposure conditions
Participants received six repeated applications of the product over a two-week period to the same area of the upper back under semi-occlusive patch conditions.
Each participant also had a control site treated with distilled water for comparison.
Skin assessments were performed throughout the study by dermatologists and trained clinical investigators.
Researchers monitored for:
+ Redness (erythema)
+ Swelling or oedema
+ Dryness
+ Itching
+ Papules
+ Vesicles
+ Fissuring
+ Other visible irritation reactions
The study used standardised irritation scoring methods including:
+ Daily Irritation Score (DIS)
+ Mean Daily Irritation Score (MDIS)
+ Mean Irritation Index (MII)
According to the study classification scale:
+ MII < 0.20 = Not irritating
The results showed:
+ No irritation reactions observed during repeated application
+ Very good skin compatibility under study conditions
The study concluded that:
+ “The product induced no reaction of irritation and has a very good skin compatibility.”
Main takeaway:
+ Every Day, Everywhere demonstrated excellent skin compatibility in a 14-day repeated application cumulative irritation study, with no observed irritation reactions under maximised exposure conditions.
MDIS = 0 indicated no measurable irritation response throughout the study period.
TL;DR
This clinical study tested whether Every Day, Everywhere caused irritation or skin reactions after repeated application under maximised patch-test conditions over a 14-day period.
31 adults with self-declared sensitive skin had the product repeatedly applied to the same area of the upper back under semi-occlusive patches to assess cumulative irritation potential and overall skin compatibility.
Researchers monitored participants throughout the study for visible skin reactions including redness, swelling, dryness, itching, papules, vesicles and other irritation responses.
The results showed that Every Day, Everywhere induced no irritation reactions throughout the study and demonstrated very good skin compatibility.
The Mean Daily Irritation Score (MDIS) remained 0 throughout testing, indicating no observed irritation or adverse skin reactions under study conditions.
Study Title:
Evaluation of the Cumulative Irritation Potential of One Product After Repeated Application Under Patch in Human - 14-Day Cumulative Irritability Test
Study Reference Number:
EUROFINS EVIC Romania ER 24/194 / 24-0612
Conducted:
Study start: 21 October 2024
Study completion: 4 November 2024
Final report issued: 22 November 2024
EUROFINS EVIC Product Testing Romania S.R.L. (2024). Evaluation of the Cumulative Irritation Potential of One Product After Repeated Application Under Patch in Human - 14-Day Cumulative Irritability Test. Study Report ER 24/194 / 24-0612. Bucharest, Romania.
This was a monocentric, simple-blind cumulative irritation patch test conducted on 31 valid adult participants aged between 20 and 70 years with self-declared sensitive skin.
The purpose of the study was to evaluate whether repeated applications of Every Day, Everywhere could:
+ Cause cumulative skin irritation
+ Trigger visible skin reactions after repeated exposure
+ Demonstrate good skin compatibility under maximised exposure conditions
Participants received six repeated applications of the product over a two-week period to the same area of the upper back under semi-occlusive patch conditions.
Each participant also had a control site treated with distilled water for comparison.
Skin assessments were performed throughout the study by dermatologists and trained clinical investigators.
Researchers monitored for:
+ Redness (erythema)
+ Swelling or oedema
+ Dryness
+ Itching
+ Papules
+ Vesicles
+ Fissuring
+ Other visible irritation reactions
The study used standardised irritation scoring methods including:
+ Daily Irritation Score (DIS)
+ Mean Daily Irritation Score (MDIS)
+ Mean Irritation Index (MII)
According to the study classification scale:
+ MII < 0.20 = Not irritating
The results showed:
+ No irritation reactions observed during repeated application
+ Very good skin compatibility under study conditions
The study concluded that:
+ “The product induced no reaction of irritation and has a very good skin compatibility.”
Main takeaway:
+ Every Day, Everywhere demonstrated excellent skin compatibility in a 14-day repeated application cumulative irritation study, with no observed irritation reactions under maximised exposure conditions.
MDIS = 0 indicated no measurable irritation response throughout the study period.
TL;DR
This clinical study tested whether Every Day, Everywhere caused irritation or skin reactions after repeated application under maximised patch-test conditions over a 14-day period.
31 adults with self-declared sensitive skin had the product repeatedly applied to the same area of the upper back under semi-occlusive patches to assess cumulative irritation potential and overall skin compatibility.
Researchers monitored participants throughout the study for visible skin reactions including redness, swelling, dryness, itching, papules, vesicles and other irritation responses.
The results showed that Every Day, Everywhere induced no irritation reactions throughout the study and demonstrated very good skin compatibility.
The Mean Daily Irritation Score (MDIS) remained 0 throughout testing, indicating no observed irritation or adverse skin reactions under study conditions.
Study Title:
Evaluation of the Cumulative Irritation Potential of One Product After Repeated Application Under Patch in Human - 14-Day Cumulative Irritability Test
Study Reference Number:
EUROFINS EVIC Romania ER 24/194 / 24-0612
Conducted:
Study start: 21 October 2024
Study completion: 4 November 2024
Final report issued: 22 November 2024
EUROFINS EVIC Product Testing Romania S.R.L. (2024). Evaluation of the Cumulative Irritation Potential of One Product After Repeated Application Under Patch in Human - 14-Day Cumulative Irritability Test. Study Report ER 24/194 / 24-0612. Bucharest, Romania.
This was a monocentric, simple-blind cumulative irritation patch test conducted on 31 valid adult participants aged between 20 and 70 years with self-declared sensitive skin.
The purpose of the study was to evaluate whether repeated applications of Every Day, Everywhere could:
+ Cause cumulative skin irritation
+ Trigger visible skin reactions after repeated exposure
+ Demonstrate good skin compatibility under maximised exposure conditions
Participants received six repeated applications of the product over a two-week period to the same area of the upper back under semi-occlusive patch conditions.
Each participant also had a control site treated with distilled water for comparison.
Skin assessments were performed throughout the study by dermatologists and trained clinical investigators.
Researchers monitored for:
+ Redness (erythema)
+ Swelling or oedema
+ Dryness
+ Itching
+ Papules
+ Vesicles
+ Fissuring
+ Other visible irritation reactions
The study used standardised irritation scoring methods including:
+ Daily Irritation Score (DIS)
+ Mean Daily Irritation Score (MDIS)
+ Mean Irritation Index (MII)
According to the study classification scale:
+ MII < 0.20 = Not irritating
The results showed:
+ No irritation reactions observed during repeated application
+ Very good skin compatibility under study conditions
The study concluded that:
+ “The product induced no reaction of irritation and has a very good skin compatibility.”
Main takeaway:
+ Every Day, Everywhere demonstrated excellent skin compatibility in a 14-day repeated application cumulative irritation study, with no observed irritation reactions under maximised exposure conditions.
MDIS = 0 indicated no measurable irritation response throughout the study period.
Every Day, Everywhere underwent repeated application clinical patch testing under dermatological supervision to assess cumulative irritation potential and overall skin compatibility in adults with sensitive skin.
Supporting study:
14-Day Cumulative Irritability Test
EUROFINS EVIC Romania ER 24/194 / 24-0612
31 valid participants with sensitive skin
Result:
“The product induced no reaction of irritation and has a very good skin compatibility.”
Every Day, Everywhere is formulated within a mildly acidic pH range of 5.0 - 5.5, consistent with commonly accepted skin-friendly pH levels.
Supporting documentation:
Every Day, Everywhere - Manufacturing & Product Specification Document
SALVIDA Version Code 23-055-06
Result: Product specification confirms a target pH range of 5.0 - 5.5.
The Eczema Association of Australasia reviewed the Barrier Reset Spray formulation and confirmed it passed their ingredient assessment. This is an assessment of the ingredients, not a clinical or efficacy test.
Supporting documentation:
Ingredient Assessment
Eczema Association of Australasia, 18 August 2026
Result: Passed.
These claims are established during formulation and confirmed again during manufacturing through detailed ingredient verification and review of all product INCI declarations.
Every Day, Everywhere is formulated without animal-derived ingredients, added fragrance or corticosteroids. All raw materials and ingredient specifications are reviewed to ensure compliance with these standards.
Barrier Reset Spray Claims
TL;DR
This claim is based on published, peer-reviewed research on hypochlorous acid as a skincare ingredient. It has not yet been tested in a clinical study on the finished Barrier Reset Spray formula.
Our manufacturer relies on this published literature to support the claim. We will update this page if product-specific testing is completed.
Supporting literature:
Status Report on Topical Hypochlorous Acid: Clinical Relevance of Specific Formulations, Potential Modes of Action, and Study Outcomes
Del Rosso JQ, Bhatia N. The Journal of Clinical and Aesthetic Dermatology. 2018;11(11):36-39.
Published literature provided by our manufacturer. Read it HERE.
TL;DR
This claim is based on published, peer-reviewed research on hypochlorous acid as a skincare ingredient. It has not yet been tested in a clinical study on the finished Barrier Reset Spray formula.
Our manufacturer relies on this published literature to support the claim that the mist leaves skin feeling refreshed.
Supporting literature:
Status Report on Topical Hypochlorous Acid: Clinical Relevance of Specific Formulations, Potential Modes of Action, and Study Outcomes
Del Rosso JQ, Bhatia N. The Journal of Clinical and Aesthetic Dermatology. 2018;11(11):36-39. Read it HERE.
Further published research provided by our manufacturer:
doi.org/10.3390/jcm12031164
doi.org/10.2147/OPTH.S132851
doi.org/10.1111/j.1467-2494.2006.00344.x
TL;DR
This claim is based on published, peer-reviewed research on hypochlorous acid as a skincare ingredient. It has not yet been tested in a clinical study on the finished Barrier Reset Spray formula.
Our manufacturer relies on this published literature to support the claim. It describes how skin looks and feels after use.
Supporting literature:
Status Report on Topical Hypochlorous Acid: Clinical Relevance of Specific Formulations, Potential Modes of Action, and Study Outcomes
Del Rosso JQ, Bhatia N. The Journal of Clinical and Aesthetic Dermatology. 2018;11(11):36-39. Read it HERE.
Further published research provided by our manufacturer:
doi.org/10.3390/jcm12031164
doi.org/10.2147/OPTH.S132851
doi.org/10.1111/j.1467-2494.2006.00344.x
Our launch batch of Barrier Reset Spray was tested for hypochlorous acid concentration before release.
Supporting documentation:
Certificate of Analysis - Batch HL-22IBA
Result: Hypochlorous acid concentration of 150 ppm, against a specification of 145 - 155 ppm.
Barrier Reset Spray is formulated to a mildly acidic target pH of 5, consistent with commonly accepted skin-friendly pH levels.
Supporting documentation:
Certificate of Analysis - Batch HL-22IBA
Result: pH 5.04 at 25°C, measured with a calibrated pH meter.
Barrier Reset Spray contains four ingredients: Aqua (Water), Sodium Chloride, Hypochlorous Acid and Acetic Acid. No preservatives are added.
The formula was put through a preservative efficacy test, which checks over 28 days that a product stays within microbiological limits without added preservatives.
Supporting documentation:
Preservative Efficacy Test
Product Information File PIF-150HOCL-001, Revision 1.1 (2026)
Result: Complies with Ph. Eur. / BP Preservative Efficacy Criteria A and USP Topical PET Criteria.
Microbiological release testing - Batch HL-22IBA
Result: Pass against ISO 17516 limits for total aerobic microbial count, yeast and mould and specified organisms.
TL;DR
This in-house test checked whether Barrier Reset Spray caused visible or felt skin reactions with repeated use.
5 adult participants applied a pre-production sample of the mist to the face and forearm twice daily for 5 days. No participant showed or reported redness, swelling, itching or stinging.
This was a small test run by our manufacturer, not an independent clinical study. It was not designed to assess sensitisation potential.
Supporting documentation:
In-Use Skin Tolerance Test (Repeated Open Application)
Report PT-150HOCL-001 (June 2026)
5 participants
Result: 0 of 5 participants showed or reported redness, swelling, itching or stinging.
TL;DR
This claim is supported by an in-house skin tolerance test of Barrier Reset Spray.
5 adult participants applied a pre-production sample of the mist to the face and forearm twice daily for 5 days. No participant showed or reported redness, swelling, itching or stinging.
Supporting documentation:
In-Use Skin Tolerance Test (Repeated Open Application)
Report PT-150HOCL-001 (June 2026)
5 participants
Result: 0 of 5 participants showed or reported redness, swelling, itching or stinging.
Barrier Reset Spray has a Cosmetic Product Safety Report prepared in line with Regulation (EC) No 1223/2009. The assessment covers leave-on use on the face, neck, body and scalp by healthy adults and children aged 3 and over, including multiple applications a day.
Supporting documentation:
Cosmetic Product Safety Report
Product Information File PIF-150HOCL-001, Revision 1.1, 25 September 2026
Result: Assessed as safe for human health when used under normal and reasonably foreseeable conditions of use. The safety assessor works for our manufacturer.
The Eczema Association of Australasia reviewed the Barrier Reset Spray formulation and confirmed it passed their ingredient assessment. This is an assessment of the ingredients, not a clinical or efficacy test.
Supporting documentation:
Ingredient Assessment
Eczema Association of Australasia, 18 August 2026
Result: Passed.
These claims are confirmed through the product’s full INCI declaration and a signed statement from our manufacturer.
Barrier Reset Spray is formulated without animal-derived ingredients, added fragrance or corticosteroids.
Supporting documentation:
Vegan Statement
Loved by Naturopaths
See why practitioners trust and recommend us.
Skin-Friendly Promise
As your support squad, we strive to make this journey as smooth as possible by addressing a common concern: will my skin react adversely to this product?
At Salvida, if you experience a genuine adverse reaction, you're covered by our 30-day Skin-Friendly Promise. T&Cs apply.*
